Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Specimen Handling 624pembrolizumab 603Magnetic Resonance Spectroscopy 550Carboplatin 444Cisplatin 394Cyclophosphamide 392Biopsy 368Paclitaxel 320Nivolumab 320Gemcitabine 313Radiotherapy 279Bevacizumab 242Dexamethasone 220fludarabine 210Docetaxel 197durvalumab 192Oxaliplatin 184venetoclax 182atezolizumab 182Fluorouracil 174Rituximab 172Pemetrexed 171Capecitabine 167Doxorubicin 164Radiation 162Radiosurgery 156Ipilimumab 143Etoposide 142Leucovorin 140Lenalidomide 136

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hizentra × 90 days × Clear all
NCT07582432 2026-05-12

SIGMA

Grifols Biologicals, LLC

Phase 3 Recruiting
49 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡